保险和再保险
What is a material increase in risk?
Our market-leading team handles thousands of occupational disease and legacy claims annually, serving insurers, self-insured companies, multinationals, and public sector bodies. With a global footprint, we track emerging risks and offer cross-border solutions.
Our occupational disease and legacy claims team handles thousands of claims each year. We are trusted partners to major composite, run-off and specialist insurers, self-insured companies, multinationals with captive cover and public sector bodies. Our global footprint allows us to monitor trends and developments of emerging risks for our clients and offer cross-border solutions.
We act in individual matters (pre- and post-litigation), long-tail and short-tail claims, group litigation, strategic litigation projects. We provide advice on handling policies, government consultations and costs.
Our expertise includes asbestos, asthma, lung disease, autoimmune disorders, back injuries, cancer, carbon monoxide poisoning, carpal tunnel syndrome, chemical and biological agent exposure, chronic obstructive pulmonary disease, dermatitis, hand-arm vibration syndrome, pneumoconiosis, upper limb disorders, respiratory diseases, work-related stress and noise-induced hearing loss. We manage product liability class actions and a significant volume of run-off disease claims.
Our innovative strategies reduce indemnity spending when handling long-tail and short-tail claims, most notably:
Our partner-led service assures quality through technical expertise, bespoke case management and information provision. Our global partner network advises on comparative law, litigation and emerging risks and issues.
We work closely as thought leaders with industry bodies to shape the legacy and latent disease policy landscape. We keep clients up to date on the latest industry developments, helping them to prepare for changes that will impact their business. We regularly work with clients to build strategies to meet anticipated emerging risks, for example claims potential from the COVID-19 pandemic and dynamic Know Your Opponent strategies.
Brilliant. They are excellent technically, and get what our needs and desires are. They provide a tailored approach that works well for us"
Chambers and Partners, 2022
Acting for the borrower (the investment vehicle of an ultra-high net worth individual) in connection with a $65,000,000 revolving credit facility to fund capital calls.
Acting for the lender on a £45,000,000 letter of credit facility made available to provide Funds at Lloyd's to support a corporate member in run-off.
Acting for the borrower (the UK subsidiary of a global US insurance company) in relation to a GBP 55,000,000 letter of credit facility for the purposes of enabling its underwriting arm to provide Funds at Lloyd’s
Acting for the borrower (a Bermudan reinsurance company) in relation to the amendment and extension of its original £106,000,000 letter of credit facility for the purpose of enabling its underwriting arm to provide Funds at Lloyd’s
Acting for the lender (a prominent UK insurance company) in relation to the refinancing of an existing £60,000,000 term loan facility and the residual intercreditor and security arrangements following the refinancing
Acting for the arrangers on a US$1,100,000,000 term loan facility financing a consortium bidding for the acquisition of Transatlantic Re
Acting for the arrangers and financiers on a US$106,500,000 term loan facility financing the acquisition of an insurance company by the Enstar Group
Acting for the lender on a US$158,000,000 letter of credit facility made available to support the obligations of a prominent UK insurance company under a whole account quota share reinsurance agreement
Acting for the financiers on a US$180,000,000 letter of credit facility to provide Funds at Lloyd’s to support and stand account for reinsurance to close business undertaken through a managed Lloyd’s syndicate
Acting for the arrangers and financiers on a US$250,000,000 revolving credit facility for Enstar Group Limited
Acting for the borrower (the investment vehicle of an ultra-high net worth individual) in connection with a $65,000,000 revolving credit facility to fund capital calls.
Acting for the lender on a £45,000,000 letter of credit facility made available to provide Funds at Lloyd's to support a corporate member in run-off.
Acting for the borrower (the UK subsidiary of a global US insurance company) in relation to a GBP 55,000,000 letter of credit facility for the purposes of enabling its underwriting arm to provide Funds at Lloyd’s
Acting for the borrower (a Bermudan reinsurance company) in relation to the amendment and extension of its original £106,000,000 letter of credit facility for the purpose of enabling its underwriting arm to provide Funds at Lloyd’s
Acting for the lender (a prominent UK insurance company) in relation to the refinancing of an existing £60,000,000 term loan facility and the residual intercreditor and security arrangements following the refinancing
Acting for the arrangers on a US$1,100,000,000 term loan facility financing a consortium bidding for the acquisition of Transatlantic Re
Acting for the arrangers and financiers on a US$106,500,000 term loan facility financing the acquisition of an insurance company by the Enstar Group
Acting for the lender on a US$158,000,000 letter of credit facility made available to support the obligations of a prominent UK insurance company under a whole account quota share reinsurance agreement
Acting for the financiers on a US$180,000,000 letter of credit facility to provide Funds at Lloyd’s to support and stand account for reinsurance to close business undertaken through a managed Lloyd’s syndicate
Acting for the arrangers and financiers on a US$250,000,000 revolving credit facility for Enstar Group Limited
Partner
Partner
Partner
Partner
Partner
Partner
Partner
Partner
See more
Our team is built on scale, expertise and a new vision for technology. With scale, comes the largest data set in the casualty space, providing more complete answers and better management information.
Read More